Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavir. - Wikidata - wikimedia - TriplyDB

Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavir.

Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavir.

http://www.wikidata.org/entity/Q37121902

about

Pharmacokinetic drug interactions of antimicrobial drugs: a systematic review on oxazolidinones, rifamycines, macrolides, fluoroquinolones, and Beta-lactams Integrated therapy for HIV and tuberculosis Current trends and intricacies in the management of HIV-associated pulmonary tuberculosis Current strategies to treat tuberculosis Transgenic mice and metabolomics for study of hepatic xenobiotic metabolism and toxicity Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients The safety, effectiveness and concentrations of adjusted lopinavir/ritonavir in HIV-infected adults on rifampicin-based antitubercular therapy.CYP3A-mediated generation of aldehyde and hydrazine in atazanavir metabolism.Initiating antiretrovirals during tuberculosis treatment: a drug safety review.Pharmacokinetics of lopinavir in HIV-infected adults receiving rifampin with adjusted doses of lopinavir-ritonavir tablets.Metabolomic screening and identification of the bioactivation pathways of ritonavir Special populations and pharmacogenetic issues in tuberculosis drug development and clinical research New drugs to treat tuberculosis.TB and HIV Therapeutics: Pharmacology Research Priorities.Clinical pharmacology, efficacy and safety of atazanavir: a review.Management of individuals requiring antiretroviral therapy and TB treatment.Rifampin combination therapy for nonmycobacterial infections.Higher rates of AIDS during the first year of antiretroviral therapy among migrants: the importance of tuberculosis.Tuberculosis and HIV co-infection: screening and treatment strategies.Treatment optimization in patients co-infected with HIV and Mycobacterium tuberculosis infections: focus on drug-drug interactions with rifamycins.The pharmacological challenges of treating tuberculosis and HIV coinfections.Addressing Antiretroviral Therapy-Associated Drug-Drug Interactions in Patients Requiring Treatment for Opportunistic Infections in Low-Income and Resource-Limited Settings.HIV and TB coinfection: using adjusted doses of lopinavir/ritonavir with rifampin.British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015

P2860

Q24631021-FC36FC97-E994-477E-8F45-0BF4D71070D9 Q26749428-7269539B-5FDC-4C87-94AC-AF01166C07C3 Q28069032-36B47DA2-2E00-4B3A-8A83-C2A8477BD37C Q28075252-B42D1A97-717F-4965-97EF-6A9C238E9F91 Q28087473-FC61256E-7294-48C1-AE85-7A378D48D926 Q28478275-4391AE87-71A0-4AA8-88A0-8F05514A1AFE Q34193050-1004EEED-0464-4C6B-9563-3B4A9AE76066 Q34702576-86DAD26E-12B7-4388-B9FD-3E579E4C3CBE Q35043048-F80553EE-DB03-4E32-AC4B-1A0C34F4BB9D Q35065871-6982E02E-DA98-4F71-957C-404132EBB050 Q35626853-9CC69593-6547-43CF-9531-2791FB877C42 Q36000004-C14870F3-F241-4B64-917A-AC5FBDCEA40B Q36018409-6F260070-B7CA-44D7-9B88-1A5DD5C3C7C3 Q36099838-5302ED5D-808C-4C3C-B904-7C3D181EA786 Q37622972-D23D7364-A9AB-4FA9-8BE5-F8201F6926B6 Q37666456-93F16597-B69F-4A30-A57F-BD6BAE6F2187 Q37672039-7CD2A73C-1BB3-402B-8CAB-8A2EB49B71BB Q37711305-55BBDF1A-BA43-4877-9344-CE8CC2C387DE Q37895251-AEE60B5E-0A3C-4D52-9633-6577AC96D2AB Q38207924-EA135D54-12C9-45A8-B75B-7DF7C3017888 Q39003762-227B7EE9-B4F6-4B85-9A9D-A9190B00DF05 Q40051462-632921EE-6E3A-410A-8B83-EDB959BD2EEE Q46488387-A45A215A-A568-4F4B-B848-6EE726EF3F73 Q57180790-FD4777B7-60B8-4AB0-8530-FD3C927C7E5F

P2860

Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavir.

http://www.wikidata.org/entity/Q37121902

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on March 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Hepatotoxicity and gastrointes ...... aily atazanavir and ritonavir.

@en

Hepatotoxicity and gastrointes ...... aily atazanavir and ritonavir.

@nl

type

label

Hepatotoxicity and gastrointes ...... aily atazanavir and ritonavir.

@en

Hepatotoxicity and gastrointes ...... aily atazanavir and ritonavir.

@nl

prefLabel

Hepatotoxicity and gastrointes ...... aily atazanavir and ritonavir.

@en

Hepatotoxicity and gastrointes ...... aily atazanavir and ritonavir.

@nl

P1433

Q37121902-EC82AE3D-EC4A-4648-90B8-A806494231E7

P1476

Q37121902-78DE39D2-BEBA-4C00-AAA0-D574035B42D0

P2093

Q37121902-05B147F7-9337-46B4-B1B7-0C656BDFA9FE

Q37121902-2BE82C19-6C7D-4B23-9D83-079A06125252

Q37121902-52D6B670-2C48-4668-B1DC-6CEB0B923235

Q37121902-5955C9CF-F6D3-4DDC-9A22-5C81E66C8FEA

Q37121902-5A478288-FEDB-4AC1-B929-18ED87AA0AF8

Q37121902-5F6E3A1D-F954-4BFA-8F03-7E7A449BA3B8

Q37121902-5FDFE1DC-52DA-4341-8030-B92F9D592D38

Q37121902-8007A40A-C122-4D87-9A96-2334AC391517

Q37121902-9390A79E-8443-49DE-BBE1-8A5D9B0EF8E8

Q37121902-9411DD2B-AA1E-41CC-BC1E-64FEFC59D6B4

P2860

Q37121902-338B26EA-E4A3-4B72-9719-875231FA7DE2

Q37121902-3CC9AF37-46CF-4065-B6F2-E1BB93194CF2

Q37121902-819FE3B1-1A6B-4756-9515-95FF3C7C2022

Q37121902-C790A4DE-8234-467D-9F6A-90DCC21D08B0

Q37121902-DA3AFF72-93B0-4DE4-A36E-D2FBACE01730

Q37121902-F4397C9C-69E1-4C08-B386-A5CD0D8750CA

P304

Q37121902-8960DE48-9E16-4FDD-83A9-8B3EF67DA60D

P31

Q37121902-80E374A8-E207-4F7E-9ACD-E7AF1CEC9668

P356

Q37121902-3A1C9440-9031-40BD-B073-5F9756507621

P407

Q37121902-9C17D989-37E5-42A4-AB7D-2B5F8DE84E25

P433

Q37121902-4B79F136-7517-4B32-89A4-3FCDF9AC231B

P478

Q37121902-A320037C-4B61-4B08-A0CB-958918562B1D

P577

Q37121902-4229A498-2E4E-4EF8-BFB3-91D28D2C5AA7

P698

Q37121902-3DDDB65A-0C3E-46C3-8D4D-81F81B5468E2

P921

Q37121902-8D98671D-7443-454E-9824-20BECDA13ED4

P932

Q37121902-CEA3B731-8484-46FB-9478-6E67D4ABEB0A

P356

QAI.0B013E318189A7DF

P1433

Journal of Acquired Immune Deficiency Syndromes

P1476

Hepatotoxicity and gastrointes ...... aily atazanavir and ritonavir.

@en

P2093

A5213 StudyTeam

http://www.w3.org/2001/XMLSchema#string

Andrew R Zolopa

http://www.w3.org/2001/XMLSchema#string

Beverly Alston-Smith

http://www.w3.org/2001/XMLSchema#string

Carol Suckow

http://www.w3.org/2001/XMLSchema#string

David W Haas

http://www.w3.org/2001/XMLSchema#string

Edward P Acosta

http://www.w3.org/2001/XMLSchema#string

John G Gerber

http://www.w3.org/2001/XMLSchema#string

Lara Hosey

http://www.w3.org/2001/XMLSchema#string

Laura Laughlin

http://www.w3.org/2001/XMLSchema#string

Michael J Child

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy volunteers.

Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily.

Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers.

High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir/ritonavir tablets.

Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.

Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis.

P304

290-293

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/QAI.0B013E318189A7DF

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

50

http://www.w3.org/2001/XMLSchema#string

P577

2009-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19194314

http://www.w3.org/2001/XMLSchema#string

P921

P932

2653210

http://www.w3.org/2001/XMLSchema#string